MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Heatmap
  • Русский
  • 中文
  • Español
  • Português
  • 日本語
  • Deutsch
  • 한국어
  • Français
  • Italiano
  • Türkçe
Celldex Therapeutics, Inc

CLDX

#1840
Celldex Therapeutics, Inc. - Common Stock
31.5 8 USD
+9862.15%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
31.36
31.60
Year Range
22.10
35.79
Daily Change
+9862.15%
Monthly Change
-3.43%
6 month change
+18.72%
Year Change
+15.93%
Previous Close
0.3 2
Open
31.4 6
Low
31.3 6
High
31.6 0
Volume
55
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. CLDX
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 2.48 B
  • Employee 198
  • Founded 1983
  • CEO N/A
  • Website www.celldex.com
  • Headquarter Delaware, United States
  • FIGI BBG000FW8LZ9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-6.96
Price to sales ratio
1 167.65

News

Zacks Zacks
CLDX KURA
2026.05.07
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Zacks
INVA CLDX
2026.05.07
Innoviva (INVA) Tops Q1 Earnings Estimates
Zacks Zacks
CLDX
2026.05.04
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
Investing Investing
CLDX
2026.03.09
Celldex Therapeutics stock hits 52-week high at $31.36
Investing Investing
CLDX
2026.02.27
Celldex presents phase 2 data for chronic urticaria treatment
Investor's Business Daily Investor's Business Daily
CLDX INVA UTHR
2026.02.26
Celldex Therapeutics Stock Earns 88 RS Rating
Investing Investing
CLDX
2026.02.26
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Investing Investing
CLDX
2026.02.25
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Investing Investing
CLDX
2026.02.25
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Investing Investing
CLDX
2026.02.25
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Investing Investing
CLDX
2026.01.06
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald
Investor's Business Daily Investor's Business Daily
CLDX GMAB KRYS
2025.12.22
Celldex Therapeutics Stock Gets RS Rating Lift

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Store
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
Scan to install from App Store Scan to install from Google Play Scan to install from Huawei AppGallery Scan to install APK
MQL5 Channels
Scan to install from App Store Scan to install from Google Play Scan to install from Huawei AppGallery Scan to install APK
Economic Calendar
Scan to install from App Store Scan to install from Google Play Scan to install from Huawei AppGallery Scan to install APK
Risk Disclosure Terms of Use Help Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd